



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

29 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	220,729	31,795	16,997	9,125	11,066	5,689	6,619	2,913	1,027
New (1st dose)	20,435	2,062	925	536	1,023	833	456	1,518	175
Total (1st)	2,808,794	438,269	174,943	117,794	138,046	91,417	78,283	49,313	13,790
Total (2nd)	168,721	27,699	8,592	5,637	14,188	5,687	5,714	7,519	1,802
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	48,548	7,839	9,329	11,211	15,483	12,321	13,248	15,194	2,325
New (1st dose)	2,946	1,693	815	1,578	1,592	1,462	399	1,893	529
Total (1st)	601,798	103,000	107,145	140,618	151,563	167,023	185,093	215,658	35,041
Total (2nd)	25,199	10,411	9,709	9,099	9,448	8,334	4,161	10,810	4,712

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,977,515	433	0.50%	419	5	4	5
	Total		15,000		14,712	162	53	73
AstraZeneca	New	1,534,425	322	0.86%	314	5	0	3
	Total		13,136		12,927	133	33	43
Pfizer	New	1,443,090	111	0.13%	105	0	4	2
	Total		1,864		1,785	29	20	30

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

29 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		680 (100)	121,351 (100)	234.05
Sex	Male	328 (48.24)	60,397 (49.77)	233.53
	Female	352 (51.76)	60,954 (50.23)	234.58
Age	80 or above	21 (3.09)	5,290 (4.36)	278.53
	70-79	37 (5.44)	8,782 (7.24)	243.46
	60-69	113 (16.62)	18,687 (15.40)	294.55
	50-59	111 (16.32)	22,466 (18.51)	259.21
	40-49	106 (15.59)	17,960 (14.80)	214.08
	30-39	101 (14.85)	16,333 (13.46)	231.83
	20-29	94 (13.82)	18,093 (14.91)	265.82
	10-19	48 (7.06)	8,487 (6.99)	171.79
0-9	49 (7.21)	5,253 (4.33)	126.62	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		4 (100)	1,825 (100)	1.50	157 (100)
Sex	Male	0 (0.00)	906 (49.64)	1.50	98 (62.42)
	Female	4 (100)	919 (50.36)	1.51	59 (37.58)
Age	80 or above	2 (50.00)	1,004 (55.01)	18.98	38 (24.20)
	70-79	2 (50.00)	523 (28.66)	5.96	52 (33.12)
	60-69	0 (0.00)	212 (11.62)	1.13	41 (26.11)
	50-59	0 (0.00)	62 (3.40)	0.28	16 (10.19)
	40-49	0 (0.00)	14 (0.77)	0.08	8 (5.10)
	30-39	0 (0.00)	7 (0.38)	0.04	1 (0.64)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.64)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.
Total	111	108	102	99	109	116	125	127	136	136	132	156	160	157

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)